CEDO
20.9.2021 09:02:14 CEST | Business Wire | Press release
Cedo, one of Europe’s largest manufacturers of recycled plastic waste bags has today revealed its Roadmap for Sustainable Business Growth. The plan is built on three pillars: People, Planet and Products and comes with targets designed to protect the earth’s resources while attracting and nurturing talent within the business.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210920005048/en/
“Our plan has been built with deep engagement from all the employees within our company,” says Rik De Vos, CEO of Cedo. “The journey to circularity will not be easy, but I have seen an immediate shift in decision making, and prioritisation of actions now that we are a purpose-led business. We are actively contributing to European and UK legislative debate to accelerate this transformation, while articulating and communicating proactively and transparently. A dream has been turned into a great journey and it pleases me enormously to see the response from everybody on our ambition.”
People
To better serve customers and employees, Cedo is committing to become positively involved in its communities in the seven countries in which it operates, investing in them both as an employer and community member while actively supporting local environmental, health and wellness projects.
With its industry-leading focus on sustainability and rewarding career and development opportunities, Cedo hopes to attract fresh and diverse talent to join its two thousand-strong workforce who are as committed to environmental sustainability as they are to innovation. “We recognise that our economic growth as a business can only be delivered by valued colleagues and communities, high quality products and a healthy planet. Our pillars are aligned to these beliefs. Real success can only come from delivering progress in all three areas,” De Vos said.
Planet
For planet, the business has committed to achieving climate neutrality across its global operations by 2030, increasing its use of renewable energy and improving energy efficiency usage.
Cedo will also improve its stewardship of water, with clear monitoring and improvement plans while reducing the overall water consumption in its operations. The business aims to send zero waste to landfill and has already achieved this target this year in the UK.
Product
To achieve circularity, Cedo has pledged to use only recycled, recyclable or sustainable materials for both packaging and product design. “We will use the Ellen MacArthur Foundation’s Circulytics measurement tool, transparently tracking its progress to become a circular business,” says Ton Emans, Director of Recycling at Cedo and President of Plastics Recyclers Europe. “We’ve been members of the Ellen MacArthur Foundation and participants of the New Plastics Economy initiative since its inception in 2016 and by working together we are confident that we can transition from a linear to a circular business model over the next few years.”
Working with customers in 34 countries and listening to their needs, Cedo is aiming to dramatically reduce plastics in its products and focus better on the use of raw materials through its eco-design process, selecting the appropriate raw material for each product and its intended life cycle. Going forward, the business will only purchase from suppliers which meet its ethical, environmental and social standards.
All of these steps that Cedo is taking towards sustainable business growth will be measured and shared in a new, fully transparent Grow With Purpose report, released every year.
Supporting nine of the United Nations Sustainable Development Goals
As well as outlining its approach to doing business, Cedo’s Roadmap for Sustainable Business Growth explains how it will work towards nine of the United Nations Sustainable Development Goals. These are Goal 3, Good Health and Well-Being; Goal 5, Gender Equality; Goal 8, Decent Work and Economic Growth; Goal 9, Industry, Innovation and Infrastructure; Goal 12, Responsible Consumption and Production; Goal 13, Climate Action; Goal 14, Life Below Water; Goal 15, Life On Land and Goal 16, Peace, Justice and Strong Institutions.
In July 2021, Cedo announced that it is one quarter of the way to achieving its 100 per cent renewable energy goal, which will see it becoming a climate neutral business by 2030.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210920005048/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release
Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release
Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
